120 related articles for article (PubMed ID: 6311866)
41. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
42. A 1,25-dihydroxyvitamin D3 receptor-like protein in mammalian and avian liver nuclei.
Duncan WE; Whitehead D; Wray HL
Endocrinology; 1988 Jun; 122(6):2584-9. PubMed ID: 2836167
[TBL] [Abstract][Full Text] [Related]
43. Physiological importance of vitamin D metabolism.
Haussler MR; Chandler JS; Pike JW; Brumbaugh PF; Speer DP; Pitt MJ
Prog Biochem Pharmacol; 1980; 17():134-42. PubMed ID: 6259650
[TBL] [Abstract][Full Text] [Related]
44. A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets.
Malloy PJ; Xu R; Cattani A; Reyes mL; Feldman D
J Bone Miner Res; 2004 Jun; 19(6):1018-24. PubMed ID: 15190891
[TBL] [Abstract][Full Text] [Related]
45. Bone mineral homeostasis in spontaneously diabetic BB rats. I. Abnormal vitamin D metabolism and impaired active intestinal calcium absorption.
Nyomba BL; Verhaeghe J; Thomasset M; Lissens W; Bouillon R
Endocrinology; 1989 Feb; 124(2):565-72. PubMed ID: 2536313
[TBL] [Abstract][Full Text] [Related]
46. 1 alpha-hydroxyvitamin D3 treatment of three patients with 1,25-dihydroxyvitamin D-receptor-defect rickets and alopecia.
Takeda E; Kuroda Y; Saijo T; Naito E; Kobashi H; Yokota I; Miyao M
Pediatrics; 1987 Jul; 80(1):97-101. PubMed ID: 3037475
[TBL] [Abstract][Full Text] [Related]
47. 1,25-dihydroxyvitamin D3-mediated transforming growth factor-beta release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiencies.
Sterck JG; Klein-Nulend J; Burger EH; Lips P
J Bone Miner Res; 1996 Mar; 11(3):367-76. PubMed ID: 8852947
[TBL] [Abstract][Full Text] [Related]
48. Absent intestinal response to calciferols in hereditary resistance to 1,25-dihydroxyvitamin D: documentation and effective therapy with high dose intravenous calcium infusions.
Bliziotes M; Yergey AL; Nanes MS; Muenzer J; Begley MG; Vieira NE; Kher KK; Brandi ML; Marx SJ
J Clin Endocrinol Metab; 1988 Feb; 66(2):294-300. PubMed ID: 2828407
[TBL] [Abstract][Full Text] [Related]
49. Effects of the administration of phosphate on nuclear 1,25-dihydroxyvitamin D3 uptake by duodenal mucosal cells of Hyp mice.
Yamamoto T; Seino Y; Tanaka H; Yamaoka K; Kurose H; Ishida M; Yabuuchi H
Endocrinology; 1988 Feb; 122(2):576-80. PubMed ID: 2828005
[TBL] [Abstract][Full Text] [Related]
50. Effects of 1,25-dihydroxyvitamin D3 on osteoblastic MC3T3-E1 cells.
Kurihara N; Ishizuka S; Kiyoki M; Haketa Y; Ikeda K; Kumegawa M
Endocrinology; 1986 Mar; 118(3):940-7. PubMed ID: 3004901
[TBL] [Abstract][Full Text] [Related]
51. Two siblings with vitamin-D-dependent rickets type II: no recurrence of rickets for 14 years after cessation of therapy.
Takeda E; Yokota I; Kawakami I; Hashimoto T; Kuroda Y; Arase S
Eur J Pediatr; 1989 Oct; 149(1):54-7. PubMed ID: 2558018
[TBL] [Abstract][Full Text] [Related]
52. The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families.
Malloy PJ; Hochberg Z; Tiosano D; Pike JW; Hughes MR; Feldman D
J Clin Invest; 1990 Dec; 86(6):2071-9. PubMed ID: 2174914
[TBL] [Abstract][Full Text] [Related]
53. Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8).
Liel Y; Kraus S; Levy J; Shany S
Endocrinology; 1992 May; 130(5):2597-601. PubMed ID: 1315250
[TBL] [Abstract][Full Text] [Related]
54. The ovary: a target organ for 1,25-dihydroxyvitamin D3.
Dokoh S; Donaldson CA; Marion SL; Pike JW; Haussler MR
Endocrinology; 1983 Jan; 112(1):200-6. PubMed ID: 6291916
[TBL] [Abstract][Full Text] [Related]
55. Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner.
Whitfield GK; Selznick SH; Haussler CA; Hsieh JC; Galligan MA; Jurutka PW; Thompson PD; Lee SM; Zerwekh JE; Haussler MR
Mol Endocrinol; 1996 Dec; 10(12):1617-31. PubMed ID: 8961271
[TBL] [Abstract][Full Text] [Related]
56. Diminished internalization and action of 1,25-dihydroxyvitamin D3 in dermal fibroblasts cultured from New World primates.
Adams JS; Gacad MA; Baker AJ; Kheun G; Rude RK
Endocrinology; 1985 Jun; 116(6):2523-7. PubMed ID: 3922744
[TBL] [Abstract][Full Text] [Related]
57. 1,25-Dihydroxyvitamin D3 increases bone alkaline phosphatase isoenzyme levels in human osteogenic sarcoma cells.
Mulkins MA; Manolagas SC; Deftos LJ; Sussman HH
J Biol Chem; 1983 May; 258(10):6219-25. PubMed ID: 6189822
[TBL] [Abstract][Full Text] [Related]
58. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D.
Balsan S; Garabédian M; Larchet M; Gorski AM; Cournot G; Tau C; Bourdeau A; Silve C; Ricour C
J Clin Invest; 1986 May; 77(5):1661-7. PubMed ID: 3009551
[TBL] [Abstract][Full Text] [Related]
59. Vitamin D3--resistant fibroblasts have immunoassayable 1,25-dihydroxyvitamin D3 receptors.
Pike JW; Dokoh S; Haussler MR; Liberman UA; Marx SJ; Eil C
Science; 1984 May; 224(4651):879-81. PubMed ID: 6326262
[TBL] [Abstract][Full Text] [Related]
60. Hereditary 1,25-dihydroxyvitamin D resistant rickets: molecular basis and implications for the role of 1,25(OH) 2D3 in normal physiology.
Feldman D; Malloy PJ
Mol Cell Endocrinol; 1990 Sep; 72(3):C57-62. PubMed ID: 1963156
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
